BBOT Analyst Ratings
BridgeBio Oncology Therapeutics Inc. (BBOT) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $718.6M, listed on NASDAQ, employing roughly 62 people, carrying a beta of 0.22 to the broader market. BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Led by Eli Wallace, public since 2025-08-12.
Consensus: Mixed from 0 analysts.
Price Targets
- Average Target
- $22.00
- High
- $24.00
- Low
- $18.00
Recent Upgrades & Downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 6, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 11, 2025 | Wedbush | maintain | Outperform | Outperform |
| Nov 25, 2025 | Wedbush | maintain | Outperform | Outperform |
| Nov 13, 2025 | Oppenheimer | maintain | Outperform | Outperform |
How to Read BBOT Analyst Coverage
Sell-side equity analysts publish three primary outputs: ratings (Strong Buy / Buy / Hold / Sell / Strong Sell, or firm-specific equivalents), price targets, and EPS / revenue estimate revisions. Rating consensus moves slowly relative to price; it reflects 12-month directional conviction rather than near-term momentum. Price targets are more responsive but typically drift behind realized price during sharp moves. The most actionable signal for options traders is a cluster of ratings actions across multiple firms within a short window, which compresses or expands implied volatility on a horizon of days to weeks and shifts the put-call skew toward the directional consensus. The recent-actions table above shows the five most recent firm-level changes; longer histories live behind aggregator sources.
For event-driven options sizing, pair the consensus rating and target distribution with the implied-volatility surface and dealer-positioning view. Aggressive target hikes from multiple firms tend to tighten put skew (downside protection becomes relatively cheaper); aggressive cuts widen put skew. The size of the IV response in the hours after a rating change is visible on the per-ticker volatility skew page and the gamma-exposure page, both of which show how dealer hedging propagates the analyst-driven flow into the listed options chain.
Learn how analyst ratings is reported and how to read the data →
Frequently asked BBOT analyst ratings questions
- What is the BBOT consensus price target?
- As of the latest aggregator update, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a consensus 12-month price target of $22.00. Target ranges run from a low of $18.00 to a high of $24.00. The target is the average of the price targets published by sell-side equity analysts covering the name.
- What is the analyst rating consensus on BBOT?
- Analyst rating consensus is not currently available for BBOT.
- What recent ratings actions has BBOT seen?
- The five most recent ratings actions on BBOT appear on the page above. Sell-side rating changes are watched for two reasons: an upgrade or downgrade with a meaningful target revision moves the consensus and can trigger short-term positioning shifts, and the firm-level rating cluster (multiple firms moving in the same direction within a short window) is a clearer signal than any single action. Options markets often price the implied-vol response within minutes of the announcement.
- How do analyst targets affect BBOT options pricing?
- Analyst target revisions tend to be priced in by the lit options market within minutes of publication, but persistent target drift over weeks does correlate with implied-volatility movement. Aggressive target hikes from multiple firms inside a single quarter tighten put skew (downside protection becomes cheaper relative to upside speculation); aggressive cuts widen put skew. The most actionable read is the implied-vol response in the hours after a target change, which is visible on the per-ticker volatility skew page.